SCHOTT Pharma KGaA 향후 성장
Future 기준 점검 1/6
SCHOTT Pharma KGaA (는) 각각 연간 9.4% 및 6.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 9.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.2% 로 예상됩니다.
핵심 정보
9.4%
이익 성장률
9.25%
EPS 성장률
| Life Sciences 이익 성장 | 20.2% |
| 매출 성장률 | 6.1% |
| 향후 자기자본이익률 | 14.17% |
| 애널리스트 커버리지 | Good |
| 마지막 업데이트 | 22 May 2026 |
최근 향후 성장 업데이트
분석 기사 • May 16
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Investors in SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) had a good week, as its shares rose 4.9% to close at €16.38...분석 기사 • Feb 14
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) defied analyst predictions to release its first-quarter results, which were...분석 기사 • Aug 15
Analysts Are Updating Their SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Estimates After Its Third-Quarter Results
Last week, you might have seen that SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) released its quarterly result to the...분석 기사 • May 18
Earnings Beat: SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) came out with its second-quarter results last week, and we wanted to see how...Recent updates
분석 기사 • May 16
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Investors in SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) had a good week, as its shares rose 4.9% to close at €16.38...
내러티브 업데이트 • May 15
1SXP: Lower Discount Rate And Solid Margins Will Support Undervalued Shares
Analysts have kept their €25.90 price target for SCHOTT Pharma KGaA unchanged, citing a slightly lower discount rate, modestly higher revenue growth and profit margin assumptions, and a marginally lower future P/E multiple in their updated models. Valuation Changes Fair Value: The €25.90 price estimate is unchanged, indicating no revision to the overall valuation outcome.
내러티브 업데이트 • Apr 29
1SXP: 2026 Guidance And Dividend Policy Will Support Future Upside
The analyst price target for SCHOTT Pharma KGaA has been adjusted slightly to €19.14 from €19.23, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that analysts see as largely offsetting one another. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed earnings guidance for the 2026 financial year, maintaining its forecast for revenue growth at constant currencies of 2 to 5% (company guidance).내러티브 업데이트 • Apr 14
1SXP: Dividend Policy And 2026 Guidance Will Support Future Profitability
Analysts have adjusted their price target for SCHOTT Pharma KGaA to €19.23 from €22.97, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed earnings guidance for the 2026 financial year, with the company expecting revenue growth at constant currencies of 2 to 5% (Corporate guidance).내러티브 업데이트 • Mar 31
1SXP: Dividend And 2026 Earnings Guidance Will Support Confidence In Undervalued Shares
Analysts have kept their price target for SCHOTT Pharma KGaA steady at €25.90, indicating relatively unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E in their updated models. What's in the News SCHOTT Pharma AG & Co. KGaA confirmed its earnings guidance for the 2026 financial year, expecting revenue growth at constant currencies of 2 to 5% (company guidance).내러티브 업데이트 • Mar 17
1SXP: Dividend And 2026 Guidance Will Support Confidence In Undervalued Shares
Analysts have maintained the price target for SCHOTT Pharma KGaA at €25.90. They cited only minor adjustments to inputs such as the discount rate, revenue growth assumptions, profit margin, and future P/E, which did not materially affect their overall valuation view.내러티브 업데이트 • Mar 03
1SXP: Dividend And Mid Term Outlook Will Support Confidence In Undervalued Shares
Analysts have maintained their €25.90 price target for SCHOTT Pharma KGaA, citing only modest adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E that they view as too small to change their overall assessment. What's in the News SCHOTT Pharma confirmed earnings guidance for the 2026 financial year, reiterating its forecast for revenue growth at constant currencies of 2 to 5% (company guidance).내러티브 업데이트 • Feb 17
1SXP: Dividend Initiation Will Support Confidence In Updated Mid Term Outlook
Analysts have nudged their price target for SCHOTT Pharma KGaA slightly lower from €26.00 to €25.90, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E multiples. What's in the News The Annual General Meeting on February 3, 2026 approved a dividend of €0.18 per share, with a payout ratio of 18% of consolidated net income (company announcement).분석 기사 • Feb 14
SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) defied analyst predictions to release its first-quarter results, which were...
내러티브 업데이트 • Feb 02
1SXP: Fair Outlook Will Balance Dividend Payout With Leadership Transition
Analysts have kept their price target for SCHOTT Pharma KGaA steady at €14.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E that they see as balancing out overall. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, payable on February 6, 2026, with an ex date of February 4, 2026, and a record date of February 5, 2026 (Key Developments).분석 기사 • Feb 02
There Is A Reason SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Price Is Undemanding
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") above 18x, you may consider...내러티브 업데이트 • Jan 19
1SXP: Dividend Initiation Will Support Confidence In Revised Long Term Outlook
Analysts have reduced their price target for SCHOTT Pharma KGaA from €36.00 to €26.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E, which point to a more conservative outlook on the shares' fair value. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, with payment scheduled for February 6, 2026, an ex dividend date on February 4, 2026, and a record date on February 5, 2026 (Key Developments).내러티브 업데이트 • Jan 05
1SXP: Leadership Transition And Dividend Policy Will Support Future Profitability
Analysts have trimmed their fair value estimate for SCHOTT Pharma KGaA from €28.28 to €22.97, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple as key drivers of the change. What's in the News SCHOTT Pharma AG & Co. KGaA announced an annual dividend of €0.18 per share, with payment scheduled for February 6, 2026, ex-date on February 4, 2026, and record date on February 5, 2026 (Key Developments).내러티브 업데이트 • Dec 20
1SXP Outlook Will Balance Lower Expectations With Dividend And Leadership Transition
Analysts have reduced their price target on SCHOTT Pharma KGaA from €22.00 to €14.00, reflecting tempered expectations for revenue growth, profit margins, and future valuation multiples in an environment characterized by higher discount rates. What's in the News SCHOTT Pharma AG & Co. KGaA declared an annual dividend of EUR 0.18 per share, payable on February 6, 2026, with an ex-dividend date of February 4, 2026, and a record date of February 5, 2026 (Key Developments).분석 기사 • Dec 15
SCHOTT Pharma KGaA (ETR:1SXP) Will Pay A Larger Dividend Than Last Year At €0.18
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) has announced that it will be increasing its periodic dividend on the 6th of...내러티브 업데이트 • Dec 06
1SXP: Leadership Transition Will Support Future Profitability And Operational Discipline
Analysts have modestly reduced their price target for SCHOTT Pharma KGaA by approximately €0.90. This reflects slightly lower assumptions for revenue growth, profit margins, and future valuation multiples, alongside a marginally higher discount rate.분석 기사 • Nov 24
A Look At The Fair Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Key Insights SCHOTT Pharma KGaA's estimated fair value is €21.30 based on 2 Stage Free Cash Flow to Equity With €18.44...내러티브 업데이트 • Nov 22
1SXP: Leadership Transition Will Drive Renewed Operational Focus And Profitability
Analysts have modestly lowered their price target for SCHOTT Pharma KGaA from €29.33 to €29.19, citing slight reductions in anticipated revenue growth and profit margins, as well as a higher discount rate used in their updated valuation models. What's in the News Christian Mias appointed as CEO of SCHOTT Pharma KGaA.분석 기사 • Nov 02
Is SCHOTT Pharma KGaA (ETR:1SXP) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...분석 기사 • Sep 19
Investor Optimism Abounds SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) But Growth Is Lacking
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 18x, you may consider...분석 기사 • Aug 15
Analysts Are Updating Their SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Estimates After Its Third-Quarter Results
Last week, you might have seen that SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) released its quarterly result to the...분석 기사 • Jul 19
These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...분석 기사 • Jun 13
Does SCHOTT Pharma KGaA (ETR:1SXP) Deserve A Spot On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...분석 기사 • May 18
Earnings Beat: SCHOTT Pharma AG & Co. KGaA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) came out with its second-quarter results last week, and we wanted to see how...분석 기사 • Apr 27
An Intrinsic Calculation For SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Suggests It's 40% Undervalued
Key Insights SCHOTT Pharma KGaA's estimated fair value is €39.60 based on 2 Stage Free Cash Flow to Equity SCHOTT...분석 기사 • Mar 22
We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Feb 12
SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Investors Are Less Pessimistic Than Expected
When close to half the companies in Germany have price-to-earnings ratios (or "P/E's") below 16x, you may consider...분석 기사 • Jan 13
Is SCHOTT Pharma AG & Co. KGaA (ETR:1SXP) Trading At A 49% Discount?
Key Insights SCHOTT Pharma KGaA's estimated fair value is €49.59 based on 2 Stage Free Cash Flow to Equity SCHOTT...
새로운 내러티브 • Dec 16
Global Expansion And Innovative Pharma Solutions Set To Boost Revenue And Profitability
SCHOTT Pharma's global expansion and innovative product offerings are expected to drive revenue growth and improve profitability by meeting market demand and increasing efficiencies.분석 기사 • Nov 25
These 4 Measures Indicate That SCHOTT Pharma KGaA (ETR:1SXP) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • Oct 27
SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) Business Is Trailing The Market But Its Shares Aren't
SCHOTT Pharma AG & Co. KGaA's ( ETR:1SXP ) price-to-earnings (or "P/E") ratio of 31.5x might make it look like a strong...분석 기사 • Sep 01
SCHOTT Pharma AG & Co. KGaA Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) investors will be delighted, with the company turning in some strong numbers...분석 기사 • Aug 07
Is There An Opportunity With SCHOTT Pharma AG & Co. KGaA's (ETR:1SXP) 31% Undervaluation?
Key Insights SCHOTT Pharma KGaA's estimated fair value is €47.81 based on 2 Stage Free Cash Flow to Equity Current...분석 기사 • Jul 01
Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts
It's been a pretty great week for SCHOTT Pharma AG & Co. KGaA ( ETR:1SXP ) shareholders, with its shares surging 11% to...분석 기사 • Jun 07
We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Mar 28
Calculating The Intrinsic Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Key Insights The projected fair value for SCHOTT Pharma KGaA is €34.80 based on 2 Stage Free Cash Flow to Equity SCHOTT...이익 및 매출 성장 예측
| 날짜 | 매출 | 이익 | 자유현금흐름 | 영업현금흐름 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 9/30/2028 | 1,158 | 178 | 109 | 264 | 9 |
| 9/30/2027 | 1,087 | 161 | 84 | 239 | 11 |
| 9/30/2026 | 1,013 | 143 | 90 | 226 | 9 |
| 3/31/2026 | 991 | 143 | 59 | 202 | N/A |
| 12/31/2025 | 995 | 150 | 11 | 158 | N/A |
| 9/30/2025 | 986 | 146 | 35 | 180 | N/A |
| 6/30/2025 | 977 | 147 | 49 | 203 | N/A |
| 3/31/2025 | 974 | 148 | 66 | 206 | N/A |
| 12/31/2024 | 956 | 135 | 46 | 184 | N/A |
| 9/30/2024 | 957 | 150 | 79 | 225 | N/A |
| 6/30/2024 | 949 | 150 | 22 | 191 | N/A |
| 3/31/2024 | 916 | 135 | -3 | 175 | N/A |
| 12/31/2023 | 906 | 158 | 36 | 220 | N/A |
| 9/30/2023 | 899 | 152 | 6 | 182 | N/A |
| 6/30/2023 | 873 | 143 | 72 | 217 | N/A |
| 9/30/2022 | 821 | 125 | 29 | 182 | N/A |
| 9/30/2021 | 649 | 101 | 34 | 132 | N/A |
| 9/30/2020 | 584 | 77 | 19 | 104 | N/A |
애널리스트 향후 성장 전망
수입 대 저축률: 1SXP 의 연간 예상 수익 증가율(9.4%)이 saving rate(1.9%)보다 높습니다.
수익 vs 시장: 1SXP 의 연간 수익(9.4%)이 German 시장(17.1%)보다 느리게 성장할 것으로 예상됩니다.
고성장 수익: 1SXP 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.
수익 대 시장: 1SXP 의 수익(연간 6.1%)이 German 시장(연간 6.8%)보다 느리게 성장할 것으로 예상됩니다.
고성장 매출: 1SXP 의 수익(연간 6.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.
주당순이익 성장 예측
향후 자기자본이익률
미래 ROE: 1SXP의 자본 수익률은 3년 후 14.2%로 낮을 것으로 예상됩니다.
성장 기업 찾아보기
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/24 08:36 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/09/30 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
SCHOTT Pharma AG & Co. KGaA는 23명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Gaurav Jain | Barclays |
| Pallav Mittal | Barclays |
| Jonathon Unwin | Barclays |